Drug registry with results analysis for brentuximab vedotin in Polish patients with CTCL.


Dear Doctors,

Therapeutic decisions in the anti-cancer treatment of CTCL patients are extremely complex. Treatment regimens seem to be poorly understood, which is why, due to the diversity of experiences and resulting scientific cognitive value, we would like to invite you to participate in a nationwide drug registry aimed at assessing the efficacy and safety of brentuximab vedotin treatment in Polish CTCL patients undergoing therapy as part of the Drug Program. Additionally, an important value of the study will be to learn about the characteristics of patients treated with brentuximab and to describe therapeutic regimens used in the treatment of CTCL.

To start collecting data in the registry, it is necessary to conclude an online agreement. Therefore, please register and follow the instructions appearing on the computer screen.

After successful registration and electronic signing of the agreement, please log in using the data obtained during the account creation process.

The BioStat® company oversees the smooth conduct of the study and data analysis.

Any questions should be directed to the Organizer's office.

BioStat Sp. z o.o.
Kowalczyka 17 Street, 44-206 Rybnik
Tel: +48 666 069 814
Email: [email protected]

BioStat. More than statistics.

Please fill out the registration form and join the study.

Registration form

Study Sponsor

Takeda Pharma sp. z o.o.
Prosta 68 Street, 00-838 Warsaw
Tel: +48 22 608 13 00/01
Fax: +48 22 608 13 03

Please log in using the data obtained after concluding the online agreement.

Forgot your password?